The Future of Clinical Trials: A Shift from Artificial to Augmented to Applied Intelligence

By Staff Writer

December 20, 2023

The Present Situation Regarding Clinical Trials

Clinical trials, the bedrock of medical advancements, must embrace significant innovation. With global spending on these trials exceeding $50 billion now and predicted to reach over $85 billion by 2030, we must question the value we’re getting from this rapidly growing industry. What is the role of Artificial intelligence (AI) in clinical trials?  There are frequently chances to address chronic health disorders that are hampered by the time and costs associated with major trials. Despite the fact that there is a clear demand for improved evidence that is supplied in a more expedient manner through clinical trials that are efficient, the fundamental costs of the majority of clinical trials have not changed.

The Role of Artificial Intelligence in Clinical Trials

AI is reshaping both scientific research and medical practice. AI holds immense potential to transform clinical research, from improving human judgement to automating tasks. Manual transfer and verification of data account for a significant portion of clinical trial costs. These processes are ripe for automation. Therefore, the breakthrough in clinical trials likely requires the integration of AI. 

Natural Language Processing in Clinical Trials

In a recent study, authors investigated if Natural Language Processing (NLP) models could effectively classify heart failure hospitalisations. They found a high agreement level between the NLP model and the trial-adjudicated case outcomes. This finding suggests that using AI for event adjudication could save significant time and costs. However, they have not yet identified the requirements for calibration, validation, and periodic performance assessment during the scaling process.

The Prospects for Artificial Intelligence in Clinical Trials

AI can significantly improve the development, execution, and dissemination of clinical trials. It can enhance efficiency and remove bias in areas like participant identification, study procedure generation, and trial material production. However, we need an oversight structure to ensure the trials don’t incorporate previous biases. By addressing the risks properly, we can safely and ethically realise the benefits of artificial intelligence in clinical trials. 

In conclusion, recent studies show that AI-enhanced clinical research is achievable and potentially beneficial. As we learn more, we must find ways to honestly communicate our limitations and failures without damaging the process’s integrity. High-quality evaluations of AI tools, using rigorous designs and analysis, are crucial to provide quality information about the benefits and risks of using AI in clinical trials. We need these kinds of publications to support the research behind AI-enhanced clinical trials and maintain trust in AI applications for these trials. 

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.